2019
Entered the oncology segment through strategic imports
Hetero Expands in Indonesia as
Years of Service
APIs
FDFs
Countries
State-of-the-art manufacturing facilities
Employees globally
Amarox Indonesia was established in March 2017, as a joint venture between Amarox Indonesia and PT Pharma Laboratories. Amarox Limited is a dedicated marketing and distribution arm of Hetero Group. Our mission is to deliver high-quality, affordable medicines that empower the people of Indonesia to lead healthier lives
Entered the oncology segment through strategic imports
Launched our Neuropsychiatry product portfolio
Expanded into
Cardiometabolic care
Today,
Our commercial and manufacturing arm, has grown to a robust team of 400+ professionals. Our state-of-the-art manufacturing facility, located in Lippo Cikarang, supports our mission by ensuring world-class production standards. To date, we have registered and commercialized over 75 molecules across key therapeutic areas.
Leading the Fight During the Pandemic
In 2020, Amarox Indonesia became the first company to launch a complete portfolio of COVID-19 treatments, including Remdesivir, Molnupiravir, and Favipiravir. During this critical time, we partnered with PT KALBE, a leading local pharmaceutical company, for the co-marketing of COVIFOR (Remdesivir) a significant step in enhancing access to life-saving medication across Indonesia.
We continue to work closely with national regulatory and health authorities, including BPOM (Indonesia FDA) and the Ministry of Health, to maintain compliance and support the country’s public health goals.
We take pride in being a trailblazer in introducing first-to-launch and first-to-file products (FTL/FFTL), as well as novel chemical entities (NCEs) in Indonesia—providing timely and differentiated treatment options for patients across multiple therapeutic areas.
First-to-Market Innovation Across Therapies
Oncology
Imatero, Erlonib, Bevas, Niltib, Afatin
Neuropsychiatry
Q-PIN (XR and IR), Zypin, Levexa Injection, Vortinex
Cardiometabolic Health
Sitazit, Dapazox, Sitazit-M
Hospital Care
Sogoma, Tigecycline
Each of these introductions addresses unmet medical needs and exemplifies our dedication to bringing affordable, effective, and timely treatments to Indonesian patients.
Our state-of-the-art manufacturing facility in Indonesia began as a greenfield project in 2017 and started commercial operations in 2019. Today, it produces over 70 high-quality medicines across key therapeutic areas, including cardiometabolic, central nervous system (CNS), gastroenterology, and pain management.
Licensed for non-betalactam oral formulations- including antiretroviral (ARV) treatments—the facility played an important role during the COVID-19 pandemic by localizing production of essential medicines like Favipiravir to support national healthcare efforts.
Integrated with advanced API manufacturing capabilities, the site ensures consistent quality across our branded generics. With more than 50 new oral medicines in the pipeline, we are committed to meeting the growing healthcare needs of Indonesia while also registering products for export to countries such as Malaysia, Cambodia, and Sri Lanka.
To support future growth, we are expanding the facility with a new production line and building a dedicated unit for oncology oral treatments—reinforcing our long-term commitment to accessible, high-quality healthcare.
Amarox Indonesia: A Trusted Partner in Healthcare Innovation
At Amarox Indonesia, we offer a comprehensive portfolio of pharmaceutical products tailored to address diverse therapeutic needs across the Indonesian healthcare landscape.
Therapeutic Areas We Serve:
Oncology
CNS
Pain Management
Cardiometabolic
Hospital Care
Antiretroviral Therapy
Our portfolio features proven, high-impact treatments across critical therapeutic segments
.png)
At Amarox Indonesia, we are committed to marketing ethically-driven, high-quality pharmaceutical products across a broad range of therapeutic areas. Our goal is to ensure that patients and healthcare providers have reliable access to innovative, affordable, and effective treatments
We are committed to building long-term partnerships that drive meaningful impact. A standout example of this was our collaboration with PT Kalbe, one of Indonesia’s leading pharmaceutical companies, to co-market COVIFOR® (Remdesivir) during the COVID-19 pandemic—a critical contribution to national healthcare efforts.
Beyond co-marketing, we offer Contract Manufacturing Organization (CMO) services, providing ready-to-launch products with existing regulatory dossiers and local manufacturing capabilities. This model supports partner companies looking to introduce second-brand products, including complex or advanced molecules that are not widely available in the Indonesian market.
Our CMO portfolio includes partnerships with top industry players such as Kalbe Farma, among others, for whom we manufacture a diverse range of products at our Indonesia facility.
We remain actively engaged with Indonesia’s regulatory authorities, including the Food and Drug Authority (BPOM) and the Ministry of Health (MoH), to ensure our products meet all local standards and contribute to the country’s public health objectives.
Join Amarox Indonesia, where innovation meets purpose. We are a fast-growing, future-ready organization committed to shaping the healthcare landscape in Indonesia and beyond.
At Amarox Indonesia, we believe our people are our greatest strength. We foster a culture of continuous learning, inclusivity, and professional growth, empowering every team member to reach their full potential.
Explore the current open positions. Connect with
us on email:
talent@hetero.com
to build a rewarding career at Amarox Indonesia.
Map and Directions
Stay Connected
Stay in touch with Amarox Indonesia for the latest updates on career opportunities, product launches, healthcare insights, and more.
We are committed to raising healthcare standards and contributing to a healthier, more resilient future for communities across Indonesia.